Faeth Therapeutics, Inc.

Listed Company

FTHCIK 0001829802NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-21.09M

Total Assets

—

Equity

—

Shares Out

1.34M

Op. Cash Flow

$-20.45M

SNSE$13.86+103.82% · past yearDBEQ Basic

Daily closing prices

Business

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company developing next-generation, tumor-microenvironment–activated biologics to modulate immune responses in cancer. It offers conditionally active monoclonal and bispecific antibody product candidates, led by solnerstotug (anti‑VISTA), and additional preclinical programs targeting VSIG4, CD39 and a pH‑selective CD28 engager. Its business is organized around its TMAb platform, discovery/preclinical activities and clinical development programs, supported by collaborations and licensing arrangements. Sensei advances candidates through clinical trial networks and relies on contract manufacturing organizations for drug substance and product supply across U.S. and international regulatory markets.

Summary from filing dated 2025-03-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	11	19	18	30	22
General and administrative	11	13	19	20	16
Long-lived asset impairment	0	1	0	—	—
Total operating expenses	22	33	37	50	37
Loss from operations	−22	−33	−37	−50	−37
Interest income	1	3	4	2	800,000
Interest expense	−32,000	−90,000	−144,000	−219,000	−670,000
Other expense, net	−4,000	−3,000	−215,000	36,000	−9,000
Net loss	−21	−30	−34	−49	−37
Net loss per common share, basic	−16.72	−24.01	−1.22	−1.58	−1.33
Net loss per common share, diluted	−16.72	−24.01	−1.22	−1.58	−1.33
Weighted-average number of shares used in computing net loss per common share, basic	1	1	28	31	28
Weighted-average number of shares used in computing net loss per common share, diluted	1	1	28	31	28
Net loss attributable to common stockholders	−21	−30	−34	−49	−37
Unrealized gain on marketable securities	14,000	196,000	795,000	−671,000	−333,000
Total other comprehensive income	14,000	196,000	795,000	−671,000	−333,000
Total comprehensive loss	−21	−30	−33	−49	−37

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	9	10	13	18	7
Marketable securities	13	31	53	89	140
Prepaid expenses	231,000	474,000	1	1	547,000
Other current assets	92,000	120,000	325,000	344,000	374,000
Total current assets	22	42	67	109	149
Right of use assets - operating leases, net	1	3	4	5	—
Right of use assets - financing leases, net	1,000	163,000	2	2	—
Property and equipment, net	82,000	417,000	1	2	5
Other non-current assets	18,000	48,000	86,000	63,000	39,000
Total assets	23	45	74	118	153
Accounts payable and accrued liabilities	1	1	2	4	2
Compensation and employee benefits liabilities	1	2	2	2	2
Operating lease liabilities, current	1	2	2	1	—
Financing lease liabilities, current	80,000	732,000	872,000	880,000	680,000
Total current liabilities	4	5	6	9	5
Operating lease liabilities, non-current	59,000	1	3	4	—
Financing lease liabilities, non-current	0	98,000	768,000	2	2
Total liabilities	4	7	9	15	7
Commitments and contingencies (Note 6)	—	—	—	—	—
Preferred stock, $0.0001 par value and 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; zero shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	—	—	—	—	—
Common stock, $0.0001 par value and 12,500,000 shares authorized as of December 31, 2025 and December 31, 2024; 1,261,685 and 1,258,940 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	0	0	3,000	3,000	3,000
Additional paid-in capital	302	300	297	302	296
Accumulated deficit	−283	−262	−232	−198	−149
Accumulated other comprehensive loss	1,000	−13,000	−209,000	−1	−333,000
Total stockholders' equity	19	38	65	103	147
Total liabilities and stockholders' equity	23	45	74	118	153

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−21	−30	−34	−49	−37
Stock-based compensation expense	1	3	4	6	6
Depreciation and amortization	100,000	600,000	600,000	600,000	685,000
Accretion on marketable securities	−699,000	−986,000	−1	231,000	615,000
Impairment of financing right-of-use asset assets	0	600,000	—	—	—
Impairment of equipment	0	342,000	—	—	—
Non-cash lease expense	2	2	1	1	—
Amortization of financing lease right-of-use assets	17,000	771,000	780,000	733,000	—
Prepaid expenses	243,000	694,000	−99,000	−582,000	828,000
Other assets	80,000	244,000	22,000	5,000	−327,000
Accounts payable and accrued liabilities	233,000	−445,000	−2	2	−1
Compensation and employee benefits	−562,000	666,000	−650,000	709,000	837,000
Operating lease liabilities	−2	−2	−1	−1	—
Other liabilities	0	−67,000	65,000	−16,000	205,000
Net cash used in operating activities	−20	−25	−32	−39	−30
Purchases of property and equipment	−16,000	−146,000	−180,000	−321,000	−2
Purchases of short-term investments	−25	−45	−21	−47	−184
Maturities of short-term investments	45	67	60	89	31
Proceeds from sale of property and equipment	250,000	0	166,000	15,000	318,000
Net cash provided by investing activities	20	22	38	50	−143
Principal payments for financing leases	−790,000	−811,000	−761,000	−629,000	−255,000
Proceeds from the sale of financing lease assets	142,000	0	—	—	—
Payment of employee restricted stock tax withholdings	−3,000	−10,000	−76,000	—	—
Employee stock purchase plan proceeds	5,000	34,000	48,000	104,000	80,000
Cash in lieu of fractional shares for reverse stock split	−1,000	0	—	—	—
Exercise of options into common stock	2,000	0	—	238,000	29,000
Net cash used in financing activities	−645,000	−787,000	−11	−287,000	164
Net decrease in cash and cash equivalents	−1	−3	−5	11	−9
Issuance of equity in exchange for compensation included in compensation and employee benefits	0	293,000	302,000	—	—
Initial measurement of operating lease right-of-use assets	0	28,000	331,000	7	—
Initial measurement of operating lease liabilities	0	28,000	331,000	7	—
Initial measurement of finance lease right-of-use assets	0	1,000	—	704,000	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Faeth Therapeutics, Inc.'s CIK number?

Faeth Therapeutics, Inc.'s SEC CIK number is 0001829802 (1829802). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Faeth Therapeutics, Inc.'s SEC filings?

All of Faeth Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Faeth Therapeutics, Inc. last report earnings?

Faeth Therapeutics, Inc. (FTH) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-225323). This is Faeth Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Faeth Therapeutics, Inc.'s most recent earnings 8-K?

Faeth Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001193125-26-225323. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Faeth Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →